Navigation Links
2011 Prix Galien USA Final Candidates Announced: Competing for Best Biotechnology Product and Best Pharmaceutical Agent

NEW YORK, July 21, 2011 /PRNewswire/ -- Honoring biomedical advances impacting both individual lives and public health in the past decade, the Prix Galien USA committee today announced the 2011 final candidates for the 5th annual Prix Galien Awards competition. The Prix Galien Award recognizes the technical, scientific and clinical research skills necessary to develop innovative medicines and devices, and is considered the industry's highest accolade.

Final candidates for the Prix Galien USA 2011 Awards are: Amgen (Prolia®)Janssen Biotech Inc. (Stelara™) Boehringer Ingelheim (Pradaxa®)Merck (Emend®)Cubist (Cubicin®) Merck (Zetia®)Dendreon (Provenge®)Novartis (Gilenya®) Eisai (Banzel®)Pfizer (Prevnar 13®)GlaxoSmithKline (Arzerra™)"Pharmaceutical research and development advances the human condition through the development of novel therapies and cures," said Gerald Weissmann, M.D., Prix Galien USA committee chair, New York University professor emeritus and editor-in-chief of The FASEB Journal. "This year's candidates demonstrate the positive impact biomedical discovery and innovation can have on improving lives of individuals."

As in past years, the committee will judge candidates as Best Pharmaceutical Agent and Best Biotechnology Product approved by the U.S. Food and Drug Administration (FDA) during the past 10 years.

"Prix Galien salutes the major contributions of the scientists and researchers who devote their lives to the development of treatments in the continuous quest to improve the health of the world's population," said Elie Wiesel, Nobel Laureate and Prix Galien USA committee member.

2011 candidates range from a vaccine to protect babies from seven strains of pneumococcal bacteria to the first oral drug therapy for relapsing forms of multiple sclerosis.  In 2010, the Prix Galien USA committee honored life sciences companies for innovations such as therapies for rare genetic disorders and diagnostic tests to indentify infections.  Last year's honorees include Luminex Corporation (xTAG ®), Novartis (Coartem®) and Merck & Co. (RotaTeq®).

The Award Ceremony, held at the Museum of Natural History in New York City, September 27, 2011, is among the most prestigious prizes for biopharmaceutical research and development.  The Prix Galien USA award committee comprises 11 individuals including Nobel Laureates, founders of major biotech companies and editors of world-renowned biology journals.  Prix Galien was first established in 1970 by French pharmacist Roland Mehl and was inaugurated in the United States in September 2007.

For details about the Prix Galien - USA award and committee, visit


UT Southwestern Medical Center at Dallas

Harvard University

UT Southwestern Medical Center at Dallas

Rockefeller University

Columbia University

Scripps Research Institute

Memorial Sloan Kettering Cancer Center

Nobel Foundation, Karolinska Institute

New York University School of Medicine

Honorary Member, Boston University

New York University School of Medicine Committee Chairman

*Nobel Laureate

The Galien Foundation is a not-for-profit, 501(c)(3) public charity. Contributions are tax deductible as provided by law.

CONTACT:  Mary Heather, Porter Novelli for Prix Galien USA, +1-212-601-8153


SOURCE Prix Galien USA
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Porter Novelli Named Agency of Record for Prix Galien USA Awards
2. Luminex Corporation Wins Prestigious 2010 Prix Galien USA Award
3. 2010 Prix Galien USA Pro Bono Humanum Award to be Presented to UNITAID for Work In Global HIV/AIDS Effort
4. Prix Galien USA Honors Innovation in Science and Biotech Industries
5. Amgen and UCB Team Up With NASA on Final Space Shuttle Mission to Conduct Preclinical Test of Sclerostin Antibody on Bone Loss
6. Glycotex, Inc. Releases Final Phase II Clinical Trials Results in the Database and Announces the Results of the Mechanism of Action Study for its Product Candidate GLYC-101
7. Next-Generation Pharmacist™ Awards Program Announces 2011 Finalists
8. Dr. Jay Yadav, CardioMEMS Founder & CEO, Selected as a Finalist for 2011 Business Person of the Year Award
9. Final Published Trial Data in The Lancet Supports Safety and Effectiveness of MicroVention-Terumos HydroCoil® Embolic System for Treatment of Cerebral Aneurysms
10. Millennium Laboratories Founder and CEO James Slattery Named Ernst & Young Entrepreneur of the Year® San Diego Finalist
11. CardioMEMS Founder & CEO Dr. Jay Yadav Named Ernst & Young Entrepreneur of the Year Finalist
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016 Research ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, Petrochemical, ... (Oral, Topical, Coating, Parenteral) - Global Forecast to 2021" ... The global pharmaceutical excipients market is ... a CAGR of 6.1% in the forecast period 2016 ...
(Date:6/23/2016)... DUBLIN , June 23, 2016 ... "Key Pharma News Issue 52" report to their offering. ... need in influenza treatment creates a favourable commercial environment for ... and growing patient base that will serve to drive considerable ... flu vaccine would serve to cap sales considerably, but development ...
(Date:6/23/2016)... , June 23, 2016 Revolutionary ... Oticon , industry leaders in advanced audiology ... of Oticon Opn ™, the world,s first internet ... possibilities for IoT devices.      (Photo: ... introduces a number of ,world firsts,: , ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the largest ... as the Medical Director of its new Mesquite-Samuell Farm facility. , “We are ... Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice Emergency ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
(Date:6/25/2016)... ... 2016 , ... Conventional wisdom preaches the benefits of moderation, whether it’s a ... the bar too high can result in disappointment, perhaps even self-loathing. However, those who ... , Research from reveals that behind the tendency to set ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Those who ... with these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, ... Marne, Michigan, has released tools for healthy coping following a traumatic event. , Trauma ...
(Date:6/24/2016)... ... ... Marcy was in a crisis. Her son James, eight, was out of control. Prone to ... , “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there ... my other children and say he was going to kill them. If we were ...
Breaking Medicine News(10 mins):